A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.
Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic. | June 9, 2023
By Chris Wack Abeona Therapeutics shares were down 7%, to $3.99, after the clinical-stage biopharmaceutical company said Friday that it received feedback for a biologics license application. | June 9, 2023
NAARDEN, The Netherlands and MIAMI, June 09, 2023 NewAmsterdam Pharma Company N.V. , a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of. | June 9, 2023
FLORHAM PARK, N.J., June 09, 2023 Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced. | June 9, 2023